Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
August 15, 2024 01:00 ET
|
Ultimovacs ASA
Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second...
Ultimovacs Announces Notice of Resignation from Deputy Board Member
August 07, 2024 07:59 ET
|
Ultimovacs ASA
Oslo, August 7, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member Ketil Fjerdingen that he has resigned from his position as deputy...
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
August 05, 2024 13:12 ET
|
Ultimovacs ASA
Adding Ultimovacs’ cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell...
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
August 01, 2024 11:20 ET
|
Ultimovacs ASA
Oslo, August 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase II...
Ultimovacs ASA announces revised terms of the employee share option program
June 24, 2024 15:00 ET
|
Ultimovacs ASA
Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option...
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
June 11, 2024 01:00 ET
|
Ultimovacs ASA
All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024 08:15 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that...
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
May 07, 2024 01:00 ET
|
Ultimovacs ASA
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company....
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
April 30, 2024 01:00 ET
|
Ultimovacs ASA
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:15 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer...